IceCure’s ProSense Shows High Success in Tumor Treatment

Icecure Medical (ICCM) has released an update.

IceCure Medical’s ProSense cryoablation technology, which destroys tumors by freezing, demonstrated a high technical success rate of 97.7% in a recent study, proving to be safe, cost-effective, and easier to manage compared to argon-based systems. The independent study, validating the use of ProSense for lung, bone, and soft tissue tumors, was conducted at the European Institute of Oncology and published in the British Journal of Radiology. IceCure’s technology is gaining traction as a minimally invasive alternative to surgical tumor removal, with ongoing studies further evaluating its efficacy in various cancers.

For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.